Saniona Pausing All Clinical Trials for PWS Drug Tesomet Due to Funding Limitations

This morning, Saniona announced they will be voluntarily pausing all Phase 2b Clinical Trials for the drug Tesomet, which is being studied as a treatment for Prader-Willi syndrome (PWS). Saniona has explained that this pause is due to funding limitations and has nothing to do with the "safety or efficacy" of the drug itself.

PWSA | USA is deeply saddened by this news, as we know it will affect many families in our community and individuals living with PWS. Please know that we are here for you and our commitment to research remains strong. If you have questions, please contact us at

Read Saniona's full press release regarding this announcement by clicking the button below.

Share this!

Scroll to top